Oncimmune, Faron Pharmaceuticals, Ondo InsurTech, Newmark Security, Quadrise – Small Cap Snapshot [Video]

Oncimmune says it’s in talks over contracts that could transform the business, with potential deals boosting revenue in 2025. For now, revenue has more than doubled to £3 million, with full results due mid-February.

Meanwhile, Faron Pharmaceuticals says it has now identified the last patient for its Phase II cancer trial. Early results on its blood cancer treatment are expected in April.

Ondo InsurTech is working with Northumbrian Water to trial LeakBot, its smart leak detector, in the North East. Similar trials with Southern Water and Portsmouth Water have already shown success.

Newmark Security says profits should keep improving every quarter. Releasing its half-year report, the security systems and services company said it expects full-year revenue growth backed by a strong sales pipeline.

And Quadrise has wrapped up its retail share offer, which doubled in size and was oversubscribed. That brings total fundraising to just over £6.5 million, including a …